Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2967-2974

  Surowiak, Paweł ^a,b,c   Pawełczyk, Konrad ^b   Maciejczyk, Adam ^c   Pudełko, Marek ^c   Kołodziej, Jerzy ^b   Zabel, Maciej ^b,d   Murawa, Dawid ^e   Drag, Margin ^f,g   Gansukh, Tserenchunt ^h   Dietel, Manfred ^a   Lage, Hermann ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Wroclaw   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e Wielkopolska Cancer Center   (Poland)

^f WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^g MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^h BURNHAM INSTITUTE   (United States)

Author keywords

ABC transporters; Chemotherapy; COX 2; Non small cell lung cancer

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYCLOOXYGENASE 2; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 55749113030     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jett JR, Scott WJ, Rivera MP and Sause WT: American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 123: 221S-225S, 2003.
2. Dillman RO, Herndon J and Seagren SL: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 Trial. J Natl Cancer Inst 88: 1210-1215, 1996.
3. Lage H: ABC transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188-199, 2003.
4. Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277: 38915-38920, 2002.
5. Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczynski M, Dietel M, Zabel M and Lage H: Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett 235: 272-280, 2006.
6. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M and Lage H: Relationship between cyclooxygenase 2 and P-glycoprotein expressions in invasive breast cancers and their prognostic significance. Breast Cancer Res 7: R862-870, 2005.
7. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
8. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathology 8: 138-140, 1987.
9. Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S and Haglund C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158: 849-853, 2001.
10. Filipits M, Haddad V, Schmid K, Huynh A, Dunat A, Andre F, Brambila E, Stahel R, Pignon J-P, Soria J-C, Popper HH, Le Chevalier T and Pirker R: Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13: 3892-3898, 2007.
11. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M: Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 131: 355-363, 2005.
12. Yokoyama H, Ishida T, Sugio K, Inoue T and Sugimachi K: Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg Today 29: 1141-1147, 1999.
13. Nakanishi Y, Kawasaki M, Bai F, Takayama K, Pei XH, Takano K, Inoue K, Osaki S, Hara N and Kiyohara C: Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer. Oncology 57: 318-323, 1999.
14. Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE 2nd, D'Amico TA and Harpole DH Jr: Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76: 187-193, 2003.
15. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M and Ochiai A: Breast cancer-resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10: 1691-1697, 2004.
16. Myatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M and Tanimoto M: Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23: 2829-2836, 2003.
17. Berger W, Elbling L, Hauptmann E and Micksche M: Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73: 84-93, 1997.
18. Giaccone G, van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ and Pinedo HM: MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 66: 760-767, 1996.
19. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS and Lee KY: Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol 36: 263-268, 2006.
20. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC and Yang PC: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115: 545-555, 2005.
21. Zhang HZ, Lu ZQ, Xie DR, Li HG, Xiong LH, Zhang H and Chen XB: Effect of cyclooxygenase-2 and matrix metalloproteinase-2 expression on prognosis of lung cancer. Ai Zheng 23: 1190-1193, 2004 (In Chinese).
22. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C and Hara N: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34: 1352-1357, 1998.
23. Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST and Kao A: Comparing the relationship of taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181: 267-273, 2003.
24. Yeh JJ, Hsu WH, Wang JJ, Ho ST and Kao A: Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70: 32-35, 2003.
25. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance: is chemoprevention against multidrug resistance possible? Anticancer Res 21: 2141-2147, 2001.
26. Ziemann C, Schäfer D, Rüdell G, Kahl GF and Hirsch-Ernst KI: the cyclooxygenase system participates in functional Mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 35: 579-588, 2002.
27. Kang HK, Lee E, Pyo H and Lim SJ: Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 4: 1358-1363, 2005.